Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first
approved by the US Food and Drug Administration in 2012. Despite correlations of …

There are many challenges to accessing PrEP and thus low uptake in the United States.
This review (2007–2017) of PrEP implementation identified barriers to PrEP and …

Background Antiretroviral chemoprophylaxis before exposure is a promising approach for
the prevention of human immunodeficiency virus (HIV) acquisition. Methods We randomly …

Abstract In the United States, rates of HIV infection are highest among black men who have
sex with men (BMSM). Pre-exposure prophylaxis (PrEP) is a highly effective form of HIV …

PrEP adherence beyond clinical trials has generally been high enough to achieve reliable
HIV prevention. Future efforts to measure and support PrEP adherence should focus on the …

Pre-exposure prophylaxis (PrEP) has demonstrated high efficacy to reduce HIV infections,
however, racial/ethnic HIV disparities continue among black MSM. The purpose of this …

With the emergence of daily oral tenofovir disoproxil fumarate and emtricitabine-based pre-
exposure prophylaxis (PrEP) use in Canada, questions have emerged concerning the …

Abstract Once-daily Truvada (Emtricitabine/Tenofovir) as a method of pre-exposure
prophylaxis (PrEP) is one of the most promising biomedical interventions to eliminate new …

Injection drug use is a key risk factor for the transmission of HIV. Prevention strategies, such
as the use of pre-exposure prophylaxis (PrEP), are effective at reducing the risk of HIV …

Objective: Implementation of HIV pre-exposure prophylaxis (PrEP) programs for populations
with highest incidence is critical to reducing new infections in the United States. Black and …